00858 EXTRAWELL PHAR
- 0.028
- +0.001+3.70%
EXTRAWELL PHAR News
EXTRAWELL PHAR: Interim Report 2023/24
Extrawell Pharmaceutical Swings to Fiscal H1 Loss on Fair Value Losses
Extrawell Pharmaceutical Holdings (HKG:0858) swung to an attributable loss of HK$237.7 million, or HK$0.0995 per share, in the fiscal first half, from a profit of HK$45.8 million, or HK$0.0192 per sha
EXTRAWELL PHAR: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2023
Extrawell Pharmaceutical: Change in Fair Value of Financial Assets Weighed on Results
Extrawell Pharmaceutical: Change in Fair Value of Financial Assets Weighed on Results
Extrawell Pharmaceutical: 1H Loss Likely Between HK$235.0M to HK$240.0M Vs. HK$46.0M Profit Year Ago
Extrawell Pharmaceutical: 1H Loss Likely Between HK$235.0M to HK$240.0M Vs. HK$46.0M Profit Year Ago
Extrawell Pharmaceutical Expects to Swing to Loss for 1H Ended September
Extrawell Pharmaceutical Expects to Swing to Loss for 1H Ended September
Premium Pharmaceutical (00858.HK) Profit Alert: Expected to lose about HK$235 million to HK$240 million in the medium term
On November 10, Gelonghui Pharmaceutical (00858.HK) announced that the company expects to record a loss of about HK$235 million and HK$240 million in the six months ending September 30, 2023, compared to a profit of about HK$46 million in the same period last year. It is expected that the conversion of profit to loss during the current period is mainly due to non-cash items, losses arising from changes in the fair value of financial assets (that is, group convertible bond investments) that are included in profit and loss at fair value, while income from changes in fair value was recorded during the corresponding period in 2022.
EXTRAWELL PHAR: Annual Report 2023
Extrawell Pharmaceutical Amends Terms of Convertible Bonds by Innovative Pharmaceutical Biotech
Extrawell Pharmaceutical Holdings (HKG:0858) issued a third amended and restated instrument to modify the terms of certain convertible bonds issued by Innovative Pharmaceutical Biotech to the company.
Extrawell Pharmaceutical's Fiscal Year 2023 Attributable Profit Falls
Extrawell Pharmaceutical Holdings' (HKG:0858) attributable profit fell to HK$129.3 million, or HK$0.0541 per share, in the fiscal year ended March 31, from HK$130.6 million, or HK$0.0546 per share, a
The annual net profit of Jingyou Pharmaceutical (00858.HK) fell 1.01% to HK$129 million
GLONGHUI, June 29丨Jingyou Pharmaceutical (00858.HK) announced that for the year ending March 31, 2023, the company's revenue was HK$72.577 million, a decrease of 1.82% over the previous year; the company's shareholders' profit for the period was HK$129 million, a decrease of 1.01% over the previous year; and the basic profit per share was HK$5.41 cents. Although earnings remained relatively stable, there was a decline in gross profit due to the government imposing mandatory factory blockade measures in Changchun City (including the Group's local production plant) from March to May 2022, which led to a decline in production. Coupled with transportation and logistics restrictions and travel restrictions
EXTRAWELL PHAR: ANNUAL RESULTS FOR THE YEAR ENDED 31 MARCH 2023
Extrawell Pharmaceutical Unit Completes Share Buyback Deal
Extrawell Pharmaceutical Holdings (HKG:0858) unit Changchun Extrawell completed the repurchase and subsequent cancellation of its own shares from vendor Jilin Zeyuan Industrial for 4.4 million yuan, a
Jingyou Pharmaceutical (00858): Changchun Jingyou completed the repurchase and cancellation of 4.57 million shares, and the company's shareholding increased to 80.46%
According to the Zhitong Finance App, Jingyou Pharmaceutical (00858) announced that 9.14% of the total issued share capital of Changchun Jingyou has been cancelled. All conditions have been met. The share repurchase and share cancellation were completed on June 19, 2023. Immediately after completion and on the date of this announcement, the total number of issued shares of Changchun Elite was reduced from 50 million to 45.43 million shares, and its registered capital was reduced from RMB 50 million to RMB 45.43 million after the shares were cancelled. As a result, the group's equity in Changchun Jingyou increased from 73.11% to 80.46%. Changchun Elite is still in the group
Extrawell Pharmaceutical to Swing to Loss in FY23
Extrawell Pharmaceutical Holdings (HKG:0858) expects a loss of about HK$190 million for the year ended March 31, as compared to a profit last year, the pharmaceutical products trader said Friday. The
Jingyou Pharmaceutical (00858) is expected to lose about HK$190 million a year from profit to loss year-on-year
According to the Zhitong Finance App, Jingyou Pharmaceutical (00858) announced that the Group expects to make a loss of about HK$190 million for the year ending March 31, 2023. Compared with the profit achieved for the year ending March 31, 2022, this is mainly due to losses stemming from changes in the fair value of the Group's convertible bond investments (non-cash items) of about HK$165 million, while revenue generated from changes in the fair value of the same non-cash project last year was approximately HK$169 million.
EXTRAWELL PHAR: PROFIT WARNING
Jingyou Pharmaceutical (00858.HK) will hold a board meeting on June 29 to approve annual results
Gelonghui, June 15, 丨 Jingyou Pharmaceutical (00858.HK) announced that the board meeting will be held on June 29, 2023 to approve the annual results of the company and its subsidiaries for the year ending March 31, 2023 and deal with other matters (if any).
EXTRAWELL PHAR: DATE OF BOARD MEETING
Jingyou Pharmaceutical (00858.HK): The Group's shares in Changchun Jingyou will increase to 80.46%
Glonghui, March 31, 丨 Jingyou Pharmaceutical (00858.HK) announced that on March 31, 2023, Changchun Jingyou (an indirect non-wholly owned subsidiary of the company with 73.11% of the company's rights) entered into a share repurchase agreement with the seller. According to this, the seller agreed to sell and Changchun Jingyou agreed to repurchase the shares to cancel the repurchase of shares, which accounted for about 9.14% of Changchun Jingyou's total issued share capital, at a cost of RMB 4.4 million. After the share repurchase and share cancellation are completed, the Group's shares in Changchun Jingyou will increase to 80.46%, while Changchun Jingyou will continue to be an indirect non-wholly owned subsidiary of the Group.
Analysis
Price Target
No Data
